Singapore, Jan. 27 -- MS Pharma Group, a leading regional pharmaceutical company in the Middle East and North Africa (MENA) region, has signed a strategic partnership agreement with Hetero Group, a global pharmaceutical company, to localise five established biosimilars across key therapeutic areas, including oncology, immunology and hematology.

The exclusive agreement will be implemented through ElKendi - MS Pharma Group's affiliate in Algeria and Hetero Biopharma - a subsidiary of Hetero Group. This marks Hetero's first local partnership in the country, representing a significant step towards strengthening Algeria's biopharmaceutical ecosystem. The combined portfolio represents an estimated total market value of $45 million in Algeria (...